---
title: "ArriVent BioPharma, Inc. (AVBP.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/AVBP.US.md"
symbol: "AVBP.US"
name: "ArriVent BioPharma, Inc."
industry: "Biotechnology"
---

# ArriVent BioPharma, Inc. (AVBP.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [arrivent.com](https://arrivent.com) |

## Company Profile

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is be...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -6.37 | 403/604 | - | - | - |
| PB | 3.15 | 233/604 | 3.45 | 3.06 | 2.77 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-24T05:00:00.000Z

Total Analysts: **11**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 11 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 23.76 |
| Highest Target | 45.00 |
| Lowest Target | 31.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/AVBP.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/AVBP.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/AVBP.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.